Why QuidelOrtho Corporation (QDEL) Went Up On Thursday
We recently published a list of In this article, we are going to take a look at where QuidelOrtho Corporation (NASDAQ:QDEL) stands against other Thursday's top-performing stocks.
The stock market extended its winning streak on Thursday as investors cheered President Donald Trump's trade deal framework between the United States and the United Kingdom.
Among Wall Street's major indices, the tech-heavy Nasdaq rallied the most, up 1.07 percent, followed by the Dow Jones, up 0.62 percent, and the S&P 500, gaining 0.58 percent.
According to Trump, the Oval Office outlined a trade deal framework. While a 10-percent baseline tariff will remain for imported goods from the UK, it could be the low end of deals with future countries.
'The final details are being written up,' Trump said. 'In the coming weeks, we'll have it all very conclusive.'
Beyond the major indices, 10 firms stood out, booking double-digit gains amid a flurry of fresh developments such as optimistic revenue guidance and impressive earnings performance, among others. In this article, let us explore Thursday's 10 top-performing stocks and detail the reasons behind their gains.
To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.
A scientist observing the results of a molecular diagnostic test.
QuidelOrtho saw its share price expand by 41.04 percent on Thursday to close at $36.46 apiece after almost wiping out its net losses during the first quarter of the year.
In a statement on Thursday, QuidelOrtho Corporation (NASDAQ:QDEL) said it narrowed its net loss by 99 percent to $12.7 million from $1.7 billion recorded in the same period last year, despite revenues dipping by 2.56 percent to $692.8 million from $711 million year-on-year.
The lag in revenues can be owed to the flat performance of its non-respiratory revenue, which was at $573 million. Meanwhile, respiratory revenues ended at $120 million, marking an 11 percent growth year-on-year.
Looking ahead, QuidelOrtho Corporation (NASDAQ:QDEL) expects revenues to settle anywhere between $2.6 billion and $2.81 billion, with adjusted EBITDA ranging from $575 million to $615 million.
For the full year, the company also targets to book between $30 million and $40 million in tariff impact, which it targets to mitigate through cost actions.
Overall, QDEL ranks 3rd on our list of Thursday's top-performing stocks. While we acknowledge the potential of QDEL as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than QDEL but that trades at less than 5 times its earnings, check out our report about this .
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TechCrunch
25 minutes ago
- TechCrunch
Google reportedly plans to cut ties with Scale AI
In Brief Meta's big investment in Scale AI may be giving some of the startup's customers pause. Reuters reports that Google had planned to pay Scale $200 million this year but is now having conversations with its competitors and planning to cut ties with the startup. Microsoft is also reportedly looking to pull back, and OpenAI supposedly made a similar decision months ago, although its CFO said the company will continue working with Scale as one of many vendors. Scale's customers include self-driving car companies and the U.S. government, but Reuters says its biggest clients are generative AI companies seeking access to workers with specialized knowledge that they can use to annotate data for training models. A Scale spokesperson declined to comment on the company's relationship with Google, but he told TechCrunch that Scale's business remains strong, and that it will continue to operate as an independent company that safeguards its customers' data. Earlier reports suggest that Meta invested $14.3 billion in Scale for a 49% stake in the company, with Scale CEO Alexandr Wang joining Meta to lead the company's efforts to develop 'superintelligence.'
CNN
28 minutes ago
- CNN
Anne Wojcicki's nonprofit wins bid to acquire genetic testing company 23andMe
A nonprofit led by Anne Wojcicki, the co-founder and former chief executive of 23andMe, won a bid to acquire the genetic testing company following its bankruptcy filing in March. Wojcicki's California-based nonprofit, TTAM Research Institute, will purchase 23andMe for $305 million, according to a news release on Friday. It's the final twist in the bidding war between TTAM and Regeneron Pharmaceuticals, which announced on May 19 that it would buy most of 23andMe's assets for $256 million. The Wall Street Journal reported that New York-based Regeneron cited 'its assessment of 23andMe's remaining value' for not submitting a higher bid. 23andMe and Regeneron did not respond to CNN's request for comment. Wojcicki stepped down from 23andMe on March 24, when the company filed for Chapter 11 bankruptcy. 23andMe's struggles drew attention in September 2024 when all seven of the company's independent directors resigned en masse, citing frustration with Wojcicki's 'strategic direction' and efforts to take the company private. In November 2024, 23andMe cut about 40% of its workforce, or roughly 200 employees, and discontinued developments of its therapies in a restructuring effort. 23andMe, which at one point was valued at $6 billion, has collected genetic data from 15 million customers through at-home DNA testing kits that used saliva samples. The testing kits offered 'personalized genetic insights' that could flag potential health risks. But 23andMe struggled to convert one-time buyers into subscribers. The company's bankruptcy filing sparked concern about data privacy, as customers worried their genetic information would be sold to a third party. Twenty-seven states and the District of Columbia filed a lawsuit on Monday against 23andMe to block the sale of genetic data without customer consent. Interested companies could use 23andMe's data to personalize their products or advertising. Genetics can be linked to food preferences, for instance. Genetic data could also be used when developing personalized medicine, Gideon Nave, an associate professor of marketing at the University of Pennsylvania's Wharton School, told CNN in March. There aren't many restrictions in place to prevent genetic discrimination, although the Genetic Information Nondiscrimination Act prevents gene information from being used for discrimination in health insurance coverage or employment. According to the news release, TTAM said that it will comply with 23andMe's privacy policies and honor existing policies regarding customer data rights, such as deleting accounts and opting out of research. 'I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe to help people access, understand and benefit from the human genome. We believe it is critical that individuals are empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish,' Wojcicki said in a news release. TTAM, an acronym for the first letters of 23andMe, will acquire 'substantially all' of 23andMe's assets, including its personal genome service, research services and Lemonaid Health, a telehealth program acquired by the company in 2021. The deal still needs to be approved by the US Bankruptcy Court for the Eastern District of Missouri. A hearing is scheduled for June 17, according to the release. CNN's Lisa Eadicicco contributed to this report.
29 minutes ago
Trump admin live updates: Crypto, Bibles, properties -- how Trump made $600M in 2024
New financial disclosure forms were released Friday showing how much President Donald Trump made in income from his various personal businesses. Earlier this week, a new analysis from the bipartisan Congressional Budget Office released Thursday showed Trump's megabill would reduce resources for the poorest U.S. households by about $1,600 per year while households in the top 10% would see gains of about $12,000 per year. Defense Secretary Pete Hegseth and Trump also defended the mobilization of National Guardsmen and Marines to Los Angeles amid objections from Democrats about their domestic deployment. Meanwhile, preparations are underway in Washington for a massive military parade to mark the Army's 250th birthday.
